XENON PHARMACEUTICALS INC. Other Comprehensive Income (Loss), Net of Tax
XENON PHARMACEUTICALS INC. (XENE) reported Other Comprehensive Income (Loss), Net of Tax of -$1.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- XENON PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was -$1.45M, a 252.27% decline year-over-year.
- XENON PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$1.55M, a 299.23% decline year-over-year.
- XENON PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $364.00K, a 89.74% decline year-over-year.
- XENON PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for the quarter ending 2025-06-30 was $949.00K.
- XENON PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for fiscal 2025 was $1.95M.
- XENON PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for fiscal 2024 was -$1.53M, a 152.51% decline from fiscal 2023.
- XENON PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for fiscal 2023 was $2.92M.
- XENON PHARMACEUTICALS INC. other comprehensive income (loss), net of tax for fiscal 2022 was -$2.01M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.45M 10-Q · filed 2026-08-06 | -$2.99M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$1.55M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $1.95M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $364.00K 10-Q · filed 2025-11-03 | $1.31M derived: sum of 2 quarters · filed 2026-08-06 | $2.09M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $949.00K 10-Q · filed 2026-08-06 | $1.73M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $776.00K 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | -$1.53M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $3.55M 10-Q · filed 2025-11-03 | $3.10M derived: sum of 2 quarters · filed 2025-11-03 | $1.41M derived: sum of 3 quarters · filed 2025-11-03 | |
| 2024-06-30 | -$443.00K 10-Q · filed 2025-11-03 | -$2.13M derived: sum of 2 quarters · filed 2025-11-03 | ||
| 2024-03-31 | -$1.69M 10-Q · filed 2025-11-03 | |||
| 2023-12-31 | $2.92M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $346.00K 10-Q · filed 2024-11-12 | -$1.13M derived: sum of 2 quarters · filed 2024-11-12 | $47.00K derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | -$1.48M 10-Q · filed 2024-11-12 | -$299.00K derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $1.18M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | -$2.01M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$1.97M 10-Q · filed 2023-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |